While understanding the trade off between tumor control probability and normal tissue complication probability lies at the heart of radiotherapy treatment planning, the reporting of the dependence of complications on dose distributions is currently inadequate. This proposal will develop new methods for reporting and combining results from individual treatment protocols that are simple to use and as unbiased and comprehensive a description of the patient treatment as possible. These methods are termed """"""""atlases"""""""" of radiotherapy outcomes statistics and dose distribution variable. The atlas method aims to comprehensively display dose distribution, medical cofactors, and outcomes statistics from radiation treatments in a manner that allows concise publication, combination with data from other institutions, and thorough analysis of dependence of the outcome endpoint on the variables displayed. In consequence, publication of atlases facilitates in depth meta-analysis of dependence of published outcome data on atlas variables;atlases allow for useful publication of treatment series with few to no complications;atlases facilitate the quantitative assessment of the potential risks and benefits of future treatments. To demonstrate the use of these tools, biophysical models and corresponding atlases will be used to analyze and display dose distribution dependence of outcome from our hypo- and single fraction radiotherapy of paraspinal, lung and liver tumors, and conventionally fractionated radiotherapy of prostate and lung. Severe pneumonitis and dose-volume histogram data from non-small-cell lung cancer patients from three institutions will be used to validate atlases as a method of data pooling and overcoming limitations of poor statistics in the biophysical modeling of complication probabilities. Atlases will be developed to that summarize dose distribution and complication data in the presence of treatment uncertainties. These atlases will be used in biophysical modeling of outcome data and the results compared with those from an exact method of including treatment uncertainties. Results will be published in atlas form to enable subsequent investigators to combine our data with their own, a crucial property in the context of the low numbers of complications usually found in individual treatment protocols. NIH and RTOG standards compliant public domain software will be created for atlas creation, maintenance and display. The adoption of atlases as a standard for reporting outcomes of radiotherapy treatment protocols has the potential to create a synergistic increase in the understanding of the dependence of outcome on dose distributions. This should permit the safe delivery of higher biologically effective doses to tumors, resulting in improved local control.

Public Health Relevance

New tools (atlases) will be developed and validated as means to overcome present limitations in reporting and modeling of dose distribution dependence of complications of radiation therapy. The addoption of atlases as a standard for reporting outcomes of radiotherapy treatment protocols has the potential to create a synergistic increase in the understanding of the dependence of outcome on dose distributions. This should permit the safe delivery of higher biologically effective doses to tumors, resulting in improved local control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA129182-01A2
Application #
7656085
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Deye, James
Project Start
2009-05-17
Project End
2011-04-30
Budget Start
2009-05-17
Budget End
2010-04-30
Support Year
1
Fiscal Year
2009
Total Cost
$467,645
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Ohri, Nitin; Tomé, Wolfgang A; Méndez Romero, Alejandra et al. (2018) Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. Int J Radiat Oncol Biol Phys :
Katsoulakis, Evangelia; Jackson, Andrew; Cox, Brett et al. (2017) A Detailed Dosimetric Analysis of Spinal Cord Tolerance in High-Dose Spine Radiosurgery. Int J Radiat Oncol Biol Phys 99:598-607
Yorke, Ellen D; Jackson, Andrew; Kuo, Li Cheng et al. (2017) Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. Int J Radiat Oncol Biol Phys 99:61-69
Rahmim, Arman; Schmidtlein, C Ross; Jackson, Andrew et al. (2016) A novel metric for quantification of homogeneous and heterogeneous tumors in PET for enhanced clinical outcome prediction. Phys Med Biol 61:227-42
Din, Shaun U; Williams, Eric L; Jackson, Andrew et al. (2015) Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain. Int J Radiat Oncol Biol Phys 93:418-24
Modh, Ankit; Rimner, Andreas; Williams, Eric et al. (2014) Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 90:1168-76
Wu, Abraham J; Williams, Eric; Modh, Ankit et al. (2014) Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors. Radiother Oncol 112:267-71
Ghadjar, Pirus; Zelefsky, Michael J; Spratt, Daniel E et al. (2014) Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 88:339-44
Ghadjar, Pirus; Jackson, Andrew; Spratt, Daniel E et al. (2013) Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity. Eur Urol 64:931-8
Liu, Fan; Yorke, Ellen D; Belderbos, José S A et al. (2013) Using generalized equivalent uniform dose atlases to combine and analyze prospective dosimetric and radiation pneumonitis data from 2 non-small cell lung cancer dose escalation protocols. Int J Radiat Oncol Biol Phys 85:182-9

Showing the most recent 10 out of 25 publications